News

Geoffrey Lynn Elevates to Chief Scientific Officer at Barinthus

Geoffrey Lynn Elevates to Chief Scientific Officer at Barinthus

Geoffrey Lynn Takes Charge as Chief Scientific Officer at Barinthus Bio

In a significant move for Barinthus Biotherapeutics plc, the company has appointed Geoffrey Lynn, M.D., Ph.D. as its new Chief Scientific Officer (CSO), effective December 1, 2024. Dr. Lynn steps into this pivotal role following the departure of Nadège Pelletier, Ph.D., who has guided the company since early 2023 and is leaving to explore other opportunities more aligned with her personal goals.

The Legacy of Leadership at Barinthus Bio

Bill Enright, Chief Executive Officer of Barinthus Bio, expressed profound gratitude for Dr. Pelletier's contributions, citing her exceptional vision and leadership that have driven the development of a fulfilling pipeline of therapeutic candidates for various autoimmune conditions. "Dr. Pelletier has played an integral role in shaping the company's research and development landscape, and her departure marks a significant transition for us," he noted. Dr. Lynn's appointment is seen as a natural progression, given his direct involvement in the company's pioneering SNAP-TI technology.

The Promise of Innovative Therapies

Dr. Lynn's tenure promises to maintain and elevate the innovative momentum at Barinthus Bio. He shared his excitement about the potential of their current projects, stating, "We have successfully registered functional cures for chronic hepatitis B with our product candidate VTP-300. Furthermore, VTP-1000, which utilizes our SNAP-TI technology, has recently entered Phase 1 clinical trials specifically addressing celiac disease.” His vision focuses on both enhancing current therapeutic pathways while also pursuing new avenues for novel therapies.

Dr. Lynn's Background and Experience

Dr. Lynn brings a wealth of experience to Barinthus Bio, having dedicated over 15 years to the biotechnology sector with a strong focus on immunotherapy. Previously, he served as the CEO and Founder of Avidea Technologies, a company he established at Johns Hopkins FastForward in 2017 before Barinthus Bio acquired it in 2021. His educational background is equally distinguished, holding both a Doctor of Medicine (M.D.) from the esteemed Johns Hopkins University School of Medicine and a D.Phil. from the University of Oxford.

About Barinthus Bio

Barinthus Bio is on the cutting edge of immunotherapeutics, striving to guide the immune system to combat chronic infections and autoimmune disorders. Their dedication stems from a mission to provide relief and hope to those suffering from severe health conditions. The company’s innovative pipeline is structured around proprietary technological platforms designed to tackle diseases such as hepatitis B and celiac disease. Their approach features VTP-300, aimed at achieving a functional cure for chronic HBV, and VTP-1000, highlighting the capabilities of SNAP-TI for celiac disease treatment. Additionally, they are initiating a Phase 1 trial for VTP-850, targeting recurrent prostate cancer.

An Eye on Future Developments

Under Dr. Lynn's guidance, Barinthus Bio seeks to navigate the complexities of biopharmaceutical development while staying true to its commitment to patients and their families. "As we look to the future, my goal is to not only capitalize on our current projects but also to explore new opportunities that could enhance our portfolio and ultimately deliver meaningful solutions to those in need," Dr. Lynn added.

Frequently Asked Questions

What is the significance of Dr. Lynn's promotion?

Dr. Lynn's promotion to CSO positions him at the helm of innovation and research for Barinthus Bio, particularly in immunotherapy development.

How will Dr. Lynn's leadership affect Barinthus Bio's pipeline?

His vast experience and knowledge are expected to drive advancements in the company's ongoing projects and foster new therapeutic discovery.

What are the primary areas of focus for Barinthus Bio?

Barinthus Bio focuses on developing immunotherapeutic candidates targeting chronic infectious diseases and autoimmune disorders.

What products are currently in clinical trials?

Currently, VTP-1000 is in a Phase 1 trial for celiac disease, while VTP-300 targets chronic hepatitis B.

Who can be contacted for more information about Barinthus Bio?

The IR and PR Manager, Jonothan Blackbourn, can provide further insights. Contact via their official channels for specific inquiries.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Accuray Finishes Key Deal, Resetting Financial Trajectory

Updated Category News Views 136

Accuray Secures the Deal, But Is the Future Bright? Every now and then in the investing world, a company pulls off a maneuver that you wish you’d thought of first. Today, folks, it's Accuray's turn. They've just wrapped up a monstrous transaction with TCW – their primary lender and shareholder – that has them feeling optimistic about the road ahead. Bold Moves to...

Continue Reading
First Horizon's $25M Bet: New Center Transforms Houston

Updated Category News Views 187

New Markets Tax Credits: A Game Changer First things first, if you're thinking this is some typical charitable write-off, think again. First Horizon Bank (NYSE: FHN) is deep in the mix of something pretty transformative in the world of finance and community support. They're not just throwing money at a problem and hoping it sticks. Nope, we're talking real strategy with a...

Continue Reading
PenFed Fuels Aggie Spirit with Blackout Game Activation

Updated Category News Views 196

A Different Kind of Game Day Experience Ah, there's nothing quite like the vibrancy of a Texas A&M game day, especially when it's a blackout event. On November 14, fans aren't just getting the good old college football thrills; they're diving headfirst into an extravaganza, courtesy of PenFed Credit Union. You might know them as the go-to credit union for military folks,...

Continue Reading
Thanksgiving in Outer Banks: Unique Traditions Await

Updated Category News Views 115

Thanksgiving Plans Off the Beaten Path Thanksgiving in the Outer Banks isn't just another holiday; it's a whole different ball game. Imagine trading in the usual family couch-potato marathon for a beachside gathering, where the sand replaces the snow, and coastal seafood joins the turkey on your dinner table. If you've been teetering on the edge of making plans, this...

Continue Reading
ACME's AI Innovation Shakes Up Filmmaking Scene

Updated Category News Views 87

The Game-Changer in Virtual Production You ever hear about the Grey Box™ phenomenon? Sounds like a sci-fi gizmo, right? Turns out, it's the real deal and ACME Media's been riding this revolutionary wave straight to the top of the film industry ladder. Their approach with this AI-driven gizmo isn't just about cutting-edge tech wizardry—it's reimagining how we shoot...

Continue Reading
Surprising Week on Wall Street: Chips Drive Gains

Updated Category News Views 163

A Wild Week in Wall Street Well, folks, what a week it’s been on Wall Street. The indexes danced the cha-cha, making gains despite closing Friday on a lower note. Despite the retreat, we've got ourselves a week where the major indexes closed higher than the previous Friday. It's not the usual story, but who ever thought stocks played by the rules? The Nasdaq Composite...

Continue Reading
Luvme Hair Offers Wig Variety for Winter Fashion

Updated Category News Views 139

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...

Continue Reading
Terra Kaffe's Big Win with Oprah's Endorsement

Updated Category News Views 109

Terra Kaffe Hits the Jackpot with Oprah Sometimes, destiny has a way of handing out golden tickets, and for Terra Kaffe, receiving a nod from Oprah Winfrey's revered list of Favorite Things for 2026 is nothing short of that. I mean, you can't underestimate the pull Mrs. O has. Her endorsement isn’t just another celebrity pat-on-the-back, it’s a megaphone blaring...

Continue Reading
Shorenstein Expands in Dallas: Strategic Play or Risk?

Updated Category News Views 127

Shorenstein's recent acquisition of International Plaza 3 isn't just about adding another high-rise to their portfolio; it's a stake in the ground, a doubling down on the Dallas real estate market. With its aim sharply set on the Lower Tollway submarket, Shorenstein is showing confidence, but the big question remains—are they spot on or walking the razor's edge?...

Continue Reading
Webull Faces Class Action: Key Details for Investors

Updated Category News Views 60

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading

Top 5 Most Recently Viewed Articles

The Brattle Group Enhances Services with New Principal

Updated Category News Views 168

The Brattle Group Enhances Services with New Principal The Brattle Group is pleased to announce the addition of Hans Weemaes as a Principal in its Financial Services & Markets and Regulatory Investigations & Enforcement practices. With an impressive background as a former economist for a federal treasury, Mr. Weemaes carries over 20 years of extensive experience in...

Continue Reading
Lumen and AWS Unite to Advance Generative AI Through Networks

Updated Category News Views 263

Lumen and AWS Join Forces in Generative AI Development Lumen Technologies (NYSE: LUMN) has announced a strategic collaboration with Amazon Web Services (AWS), an Amazon.com company (NASDAQ: AMZN), aiming to enhance network operations and delivery capabilities. This partnership is set against the backdrop of expanding AI-driven services that demand efficient and robust...

Continue Reading
Sean Trahan Joins Citrin Cooperman: New Tax Lead

Updated Category News Views 46

Citrin Cooperman's Strategic Tax Move If there's one phrase that can spark a debate at a financial water cooler, it's 'transfer pricing.' Today, Citrin Cooperman is throwing its hat further into that ring with the appointment of Sean Trahan as head of their new Transfer Pricing and Value Chain Optimization Practice. This isn't just another reshuffling of office...

Continue Reading
Modernization: Strengthening Ties Between China and Africa

Updated Category News Views 64

Modernization: Strengthening Ties Between China and Africa Recently, China Everything released an engaging short video titled "A shared path to modernization." This video highlights the successful collaboration between China and Africa, showcasing the strong friendship that has developed between the people of these two regions. The Unity of Aspirations As the largest...

Continue Reading
Okeanis Eco Tankers Announces Dividend Details for Shareholders

Updated Category News Views 129

Okeanis Eco Tankers Declares Dividend for Common Shares Okeanis Eco Tankers Corp. (NYSE: ECO / OSE: OET) has announced a significant dividend for its shareholders. The board of directors has officially declared a dividend on its common shares, representing a fruitful opportunity for investors as they participate in the company's success. This dividend is a reflection of...

Continue Reading